Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors
ACS Medicinal Chemistry Letters2014Vol. 6(1), pp. 37–41
Citations Over TimeTop 24% of 2014 papers
Paul A. Barsanti, Robert J. Aversa, Xianming Jin, Yue Pan, Yipin Lu, R.A. Elling, Rama Jain, Mark Knapp, Jiong Lan, Xiaodong Lin, Patrick J. Rudewicz, Janet Sim, Lorena Taricani, George Thomas, Linda Xiao, Qin Yue
Abstract
A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines. Use of PI3Kα mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chemistry designs. Detailed DMPK studies involving cyanide and GSH as trapping agents during microsomal incubations, in addition to deuterium-labeled compounds as mechanistic probes uncovered the molecular basis for the observed CYP3A4 TDI in the series.
Related Papers
- A GEOMETRIC MEAN IN THE FURUTA INEQUALITY(2002)
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- Коммуникaтивно- прaгмaтический aнaлиз дипломaтических бумaг (нa основе вербaльных нот)(2018)
- → ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ(2023)